Lipid-polymer hybrid nanoparticles carrying doxorubicin and edelfosine combo for synergistic anticancer effect against drug-resistant Osteosarcoma

Ping Yang, Lian Zhang, Tian Wang, Qi Liu, Jing Wang, Yaling Wang, Zhiquan Tu, Feng LinResearch 2020 · DOI

Abstract

Abstract In this study, we have prepared a novel folate receptor-targeted doxorubicin (DOX) and edelfosine (ET)-loaded lipid polymer hybrid nanoparticle to enhance the anticancer efficacy in osteosarcoma. The dual-drug loaded nanoparticles showed a nanosized morphology and physiological stability. The targeted nanoparticles showed enhanced cellular internalization and subcellular distribution in MG63 cancer cells compared to that of non-targeted nanoparticles. Among many ratios of DOX and ET, 1:1 ratiometric combinations of drugs were observed to be highly synergistic in killing the cancer cells. MTT assay and caspase-3/7 activity assay clearly showed the superior anticancer efficacy of DE-FPLN formulations in inducing the cancer cell death. In vitro results indicate that the co-administration of two drugs in a folic acid-targeted nanoparticle could potentially induce the apoptosis and cell death. In vivo results displayed the potency of tumor cell killing and significant suppression of tumor growth without any detectable side effects. The lipid polymer hybrid nanocarriers with multiple properties of high drug loading, sequential and ratiometric drug release, improved physiological stability, prolonged blood circulation, and tumor-specific targeting are promising for the delivery of multiple drugs in the treatment of osteosarcoma.
BibTeX
@inproceedings{yang2020lipid,
  author = {Ping Yang and Lian Zhang and Tian Wang and Qi Liu and Jing Wang and Yaling Wang and Zhiquan Tu and Feng Lin},
  title = {{Lipid-polymer hybrid nanoparticles carrying doxorubicin and edelfosine combo for synergistic anticancer effect against drug-resistant Osteosarcoma}},
  booktitle = {Research},
  year = {2020},
  doi = {10.21203/rs.3.rs-15987/v1},
}
Figure